Principal Financial Group Inc. lifted its stake in Celldex Therapeutics, Inc. (NASDAQ:CLDX – Free Report) by 13.2% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 12,848 shares of the biopharmaceutical company’s stock after purchasing an additional 1,497 shares during the period. Principal Financial Group Inc.’s holdings in Celldex Therapeutics were worth $354,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also recently modified their holdings of CLDX. Allspring Global Investments Holdings LLC increased its stake in shares of Celldex Therapeutics by 77.5% in the 2nd quarter. Allspring Global Investments Holdings LLC now owns 1,136 shares of the biopharmaceutical company’s stock worth $39,000 after purchasing an additional 496 shares in the last quarter. Point72 Hong Kong Ltd increased its stake in Celldex Therapeutics by 57.9% in the 1st quarter. Point72 Hong Kong Ltd now owns 1,394 shares of the biopharmaceutical company’s stock worth $47,000 after buying an additional 511 shares in the last quarter. Tower Research Capital LLC TRC increased its stake in Celldex Therapeutics by 604.9% in the 1st quarter. Tower Research Capital LLC TRC now owns 2,178 shares of the biopharmaceutical company’s stock worth $78,000 after buying an additional 1,869 shares in the last quarter. Cubist Systematic Strategies LLC increased its stake in Celldex Therapeutics by 78.8% in the 1st quarter. Cubist Systematic Strategies LLC now owns 2,782 shares of the biopharmaceutical company’s stock worth $100,000 after buying an additional 1,226 shares in the last quarter. Finally, Headlands Technologies LLC purchased a new stake in Celldex Therapeutics in the 2nd quarter worth $135,000.
Celldex Therapeutics Stock Down 1.2 %
CLDX opened at $37.59 on Tuesday. The firm has a 50-day simple moving average of $37.72 and a two-hundred day simple moving average of $31.47. Celldex Therapeutics, Inc. has a 52 week low of $22.11 and a 52 week high of $47.91. The company has a market capitalization of $1.78 billion, a PE ratio of -14.24 and a beta of 1.41.
Analyst Upgrades and Downgrades
Celldex Therapeutics Company Profile
Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, which uses the company's proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation.
- Five stocks we like better than Celldex Therapeutics
- How to Invest in Apparel Stocks
- 3 attractive stocks that insiders are buying
- How to Invest in Biotech Stocks
- Alpha and Omega Semiconductor ready to bounce, DOJ cloud lifts
- Russell 2000 Index, How Investors Use it For Profitable Trading
- Wendy’s vs Shake Shack: Out with the new, in with the old?
Receive News & Ratings for Celldex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.